Methods and compositions related to accelerated humoral affinity

Abstract

Disclosed herein is a vaccine comprising an antigen and a protein, peptide, or carbohydrate of Chlamydia spp., or a fragment thereof, wherein the antigen is not derived from a Chlamydia spp. Also disclosed are methods of treating or preventing diseases comprising administering to a subject a vaccine, wherein the vaccine comprises art antigen and a protein, peptide, or carbohydrate of Chlamydia spp., or a fragment thereof, wherein the antigen is not derived from a Chlamydia spp.

1 - 12 . (canceled) 
     
     
         13 . A method of treating or preventing disease or infection in a subject, the method comprising administering to the subject an antigen and an effective amount of an adjuvant, wherein the adjuvant comprises a separate, whole, inactivated  Chlamydia  spp. bacteria, wherein the antigen is not derived from  Chlamydia  spp., and further wherein the antigen and adjuvant are chemically conjugated; thereby preventing a disease or infection in the subject. 
     
     
         14 . The method of  claim 13 , wherein the  Chlamydia  spp. comprises  C. trachomatis, C. psittaci, C. muridarum , or  C. pneumoniae.    
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . The method of  claim 13 , wherein the antigen is viral. 
     
     
         18 . The method of  claim 17 , wherein the antigen is derived from HIV. 
     
     
         19 . The method of  claim 18 , wherein the antigen is an env protein, peptide, or fragment thereof. 
     
     
         20 . The method  claim 13 , wherein the antigen is tumor-related. 
     
     
         21 . The method of  claim 13 , wherein the subject is a mammal. 
     
     
         22 . The method of  claim 21 , wherein the mammal is a human. 
     
     
         23 - 38 . (canceled) 
     
     
         39 . The method of  claim 20 , wherein the antigen is tumor-specific. 
     
     
         40 . The method of  claim 13 , wherein the antigen and the adjuvant are in the form of a vaccine. 
     
     
         41 . The method of  claim 40 , wherein the vaccine further comprises a pharmaceutically acceptable carrier. 
     
     
         42 . The method of  claim 13 , wherein the pharmaceutical compositions may be given following, preceding, in lieu of, or in combination with, other therapies relating to generating an immune response or treating or preventing disease. 
     
     
         43 . The method of  claim 42 , wherein the other therapy comprises antiviral medication. 
     
     
         44 . The method of  claim 42 , wherein the other therapy comprises an intra-tumor implant of stimulated allogeneic lymphocytes.